Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AstraZeneca PLC Director's Dealing 2016

Jun 14, 2016

5229_dirs_2016-06-14_733fbf62-7429-4bbc-b443-e8334e11bc94.html

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1638B

AstraZeneca PLC

14 June 2016

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 13 June 2016, the interest of Pascal Soriot, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.

The change in interest relates to the vesting of an award of shares made in June 2013 under the AstraZeneca Performance Share Plan.

Following the application of performance measures specified at the time of grant, Mr Soriot has become beneficially entitled to 78% of the shares originally awarded. In accordance with the plan rules, any unvested part of the award has immediately and irrevocably lapsed.

After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Soriot has become beneficially entitled to and has received 84,316 shares into a personal brokerage account.

For tax purposes, the fair market value of the shares at vest was 3852 pence per share being the closing price of AstraZeneca ordinary shares on the last trading day preceding the vesting day.

A C N Kemp

Company Secretary

14 June 2016

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUSSURNRANAAR